50.47
前日終値:
$49.76
開ける:
$49.97
24時間の取引高:
1.74M
Relative Volume:
0.63
時価総額:
$61.97B
収益:
$48.62B
当期純損益:
$6.80B
株価収益率:
18.00
EPS:
2.8038
ネットキャッシュフロー:
$7.62B
1週間 パフォーマンス:
+2.23%
1か月 パフォーマンス:
-5.04%
6か月 パフォーマンス:
+4.15%
1年 パフォーマンス:
+1.94%
Sanofi Adr Stock (SNY) Company Profile
SNY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
50.47 | 127.40B | 48.62B | 6.80B | 7.62B | 2.8038 |
![]()
LLY
Lilly Eli Co
|
769.88 | 648.68B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
155.03 | 369.52B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
189.83 | 327.88B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVO
Novo Nordisk Adr
|
74.63 | 308.64B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
NVS
Novartis Ag Adr
|
118.02 | 222.36B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
2025-03-21 | 開始されました | Goldman | Neutral |
2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
2024-07-26 | 繰り返されました | Argus | Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-10-30 | ダウングレード | Stifel | Buy → Hold |
2023-09-06 | アップグレード | Berenberg | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
2022-12-13 | 再開されました | Morgan Stanley | Overweight |
2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
2022-08-09 | ダウングレード | UBS | Buy → Neutral |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 開始されました | Deutsche Bank | Sell |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
2020-03-11 | アップグレード | Goldman | Neutral → Buy |
2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 開始されました | Bernstein | Outperform |
2019-08-14 | アップグレード | UBS | Neutral → Buy |
2018-12-11 | アップグレード | Jefferies | Hold → Buy |
2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
2018-03-23 | アップグレード | Liberum | Hold → Buy |
2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - GlobeNewswire Inc.
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive Investors
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
Can Navitas Semiconductor Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Procore Technologies Inc (PCOR) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Navigating TREE Stock: LendingTree Inc Journey - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
Analyzing the Impact of Earnings Reports on Sunstone Hotel Investors Inc Inc. (SHO) Price Performance - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
TTWO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
CTRE’s Market Whiplash: 5.78% YTD Rise, 0.22% Rise in 30 Days - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Canadian National Railway Co: Navigating Market Fluctuations with a 62.62B Market Cap - investchronicle.com
DUOL’s 2023 Market Dance: Up 43.43% – Time to Invest? - investchronicle.com
CF Industries Holdings Inc (CF) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Sumitomo Mitsui Financial Group Inc ADR (SMFG) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Vipshop Holdings Ltd ADR Inc. (VIPS) Price Performance: The Role of Supply and Demand - investchronicle.com
Uncovering the Potential of American Homes 4 Rent (AMH) Stock - investchronicle.com
The Significance of Moving Averages in Live Nation Entertainment Inc Inc. (LYV) Price Performance - investchronicle.com
APG’s Stochastic Averages Dip: Analyzing APi Group Corporation’s Stock Performance - investchronicle.com
CNMD’s 52-Week Rollercoaster: From $46.00 to $78.58 – What’s Next for Investors? - investchronicle.com
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):